ZUMA-7 Trial: How CAR-T Is Redefining LBCL Treatment

Frederick Locke, MD, of the Moffitt Cancer Center, described the ZUMA-7 trial of axicabtagene ciloleucel (axi-cel) versus standard of care for patients with relapsed or refractory large B-cell lymphoma (LBCL).

“That study enrolled hundreds of patients across sites around the world and showed that CAR [chimeric antigen receptor] T-cell therapy not only is the preferable treatment to existing chemotherapy and transplant options in terms of leading to remission and sustained remission, but patients randomized to the CAR T-cell therapy arm had better overall survival…the results are remarkable,” he commented.

Dr. Locke also shared upcoming CAR-T research, including a phase 3 randomized trial evaluating whether donor-derived CAR-T cells could benefit patients with lymphoma. Additionally. Dr. Locke and his team are assessing the role of diet and exercise interventions on patient quality of life.

Read more: Frederick Locke, MD, Awarded Researcher of the Year by Moffitt Cancer Center